SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc.
NNVC 1.660-2.4%Oct 31 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: old 'n cranky who wrote (12781)5/27/2020 4:55:30 AM
From: HardToFind  Read Replies (1) of 12871
 
HCoV-NL63 uses the same ACE2 receptor as the SARS-CoV-2 virus causing the pandemic, and also exhibits similar disease pathology in human infections, albeit causing a much milder disease. HCoV-NL63 can be used in a BSL2 lab whereas SARS-CoV-2 currently requires BSL3/BSL4 labs. Therefore, the Company believes hCoV-NL63 serves as a useful model for drug development against SARS-CoV-2.
  1. HCoV-NL63 uses the same ACE2 receptor as the SARS-CoV-2
  2. [HCoV-NL63] exhibits similar disease pathology in human infections...but milder
  3. Mild enough that HCoV-NL63 can be used in a BSL2 lab [which, as you know, NNVC has]
Therefore, the Company believes hCoV-NL63 serves as a useful model for drug development against SARS-CoV-2.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News